PMGC Holdings Inc. (ELAB)
NASDAQ: ELAB · Real-Time Price · USD
4.420
-0.360 (-7.53%)
At close: Sep 21, 2026, 4:00 PM EDT
4.400
-0.020 (-0.45%)
After-hours: Sep 21, 2026, 4:39 PM EDT
PMGC Holdings Employees
As of December 31, 2025, PMGC Holdings had 34 total employees, including 32 full-time and 2 part-time employees. The number of employees increased by 31 or 1,033.33% compared to the previous year.
Employees
34
Change (1Y)
31
Growth (1Y)
1,033.33%
Revenue / Employee
$75,844
Profits / Employee
-$396,637
Market Cap
3.58M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 34 | 31 | 1,033.33% | 32 | 2 |
| Dec 31, 2024 | 3 | -15 | -83.33% | 2 | 1 |
| Dec 31, 2023 | 18 | 4 | 28.57% | 18 | 0 |
| Jun 30, 2023 | 16 | - | - | 16 | 0 |
| Mar 31, 2023 | 14 | - | - | 14 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| GeoVax Labs | 19 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Revelation Biosciences | 9 |
| Jupiter Neurosciences | 5 |
| Cadrenal Therapeutics | 5 |
ELAB News
- 3 days ago - PMGC secures 5-year royalty stream from Elevai Skincare sale - TheFly
- 3 days ago - PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings - GlobeNewsWire
- 20 days ago - NorthStrive Biosciences Expands AI-Driven Drug Discovery Program with Yuva Biosciences, Advancing Four Novel AI-Discovered Compounds Toward Lead Nomination for Potential Cardiac Disease and Obesity Therapeutic Applications - GlobeNewsWire
- 26 days ago - PMGC terminates non-binding letter of intent to acquire Arizona company - TheFly
- 26 days ago - PMGC Holdings Terminates Previously Announced Acquisition LOI Following Due Diligence Review; Reaffirms Disciplined M&A Strategy and Expands Investment Across Aerospace & Defense Manufacturing Portfolio - GlobeNewsWire
- 27 days ago - PMGC announces term sheet with Orbit2Orbit - TheFly
- 27 days ago - PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss - GlobeNewsWire
- 4 weeks ago - NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight - GlobeNewsWire